The Withdrawal Assessment Tool-1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients
Linda S Franck, Sion Kim Harris, Deborah J Soetenga, June K Amling, Martha A Q Curley, Linda S Franck, Sion Kim Harris, Deborah J Soetenga, June K Amling, Martha A Q Curley
Abstract
Objective: To develop and test the validity and reliability of the Withdrawal Assessment Tool-1 for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients.
Design: Prospective psychometric evaluation. Pediatric critical care nurses assessed eligible at-risk pediatric patients for the presence of 19 withdrawal symptoms and rated the patient's overall withdrawal intensity using a Numeric Rating Scale where zero indicated no withdrawal and 10 indicated worst possible withdrawal. The 19 symptoms were derived from the Opioid and Benzodiazepine Withdrawal Score, the literature and expert opinion.
Setting: Two pediatric intensive care units in university-affiliated academic children's hospitals.
Patients: Eighty-three pediatric patients, median age 35 mos (interquartile range: 7 mos-10 yrs), recovering from acute respiratory failure who were being weaned from more than 5 days of continuous infusion or round-the-clock opioid and benzodiazepine administration.
Interventions: Repeated observations during analgesia and sedative weaning. A total of 1040 withdrawal symptom assessments were completed, with a median (interquartile range) of 11 (6-16) per patient over 6.6 (4.8-11) days.
Measurements and main results: Generalized linear modeling was used to analyze each symptom in relation to withdrawal intensity ratings, adjusted for site, subject, and age group. Symptoms with high redundancy or low levels of association with withdrawal intensity ratings were dropped, resulting in an 11-item (12-point) scale. Concurrent validity was indicated by high sensitivity (0.872) and specificity (0.880) for Withdrawal Assessment Tool-1 > 3 predicting Numeric Rating Scale > 4. Construct validity was supported by significant differences in drug exposure, length of treatment and weaning from sedation, length of mechanical ventilation and intensive care unit stay for patients with Withdrawal Assessment Tool-1 scores > 3 compared with those with lower scores.
Conclusions: The Withdrawal Assessment Tool-1 shows excellent preliminary psychometric performance when used to assess clinically important withdrawal symptoms in the pediatric intensive care unit setting. Further psychometric evaluation in diverse at-risk groups is needed.
Figures
![Figure 1. Receiver Operator Characteristic Curve: WAT-1…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2775493/bin/nihms-78618-f0001.jpg)
Figure 2. Comparison of opioid exposure levels…
Figure 2. Comparison of opioid exposure levels by WAT-1 scores. (n=83)
Legend: Panel a. Greater…
- Assessment of withdrawal symptoms in pediatric intensive care patients, a new future?Ista E, van der Voort E. Ista E, et al. Pediatr Crit Care Med. 2008 Nov;9(6):654-5. doi: 10.1097/PCC.0b013e31818c86e7. Pediatr Crit Care Med. 2008. PMID: 18997597 No abstract available.
- Psychometric evaluation of the Sophia Observation withdrawal symptoms scale in critically ill children.Ista E, de Hoog M, Tibboel D, Duivenvoorden HJ, van Dijk M. Ista E, et al. Pediatr Crit Care Med. 2013 Oct;14(8):761-9. doi: 10.1097/PCC.0b013e31829f5be1. Pediatr Crit Care Med. 2013. PMID: 23962832
- Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients.Franck LS, Scoppettuolo LA, Wypij D, Curley MAQ. Franck LS, et al. Pain. 2012 Jan;153(1):142-148. doi: 10.1016/j.pain.2011.10.003. Epub 2011 Nov 16. Pain. 2012. PMID: 22093817 Free PMC article.
- Opioid and benzodiazepine withdrawal symptoms in paediatric intensive care patients.Franck LS, Naughton I, Winter I. Franck LS, et al. Intensive Crit Care Nurs. 2004 Dec;20(6):344-51. doi: 10.1016/j.iccn.2004.07.008. Intensive Crit Care Nurs. 2004. PMID: 15567675
- Opioid and Benzodiazepine Weaning in Pediatric Patients: Review of Current Literature.Fenn NE 3rd, Plake KS. Fenn NE 3rd, et al. Pharmacotherapy. 2017 Nov;37(11):1458-1468. doi: 10.1002/phar.2026. Epub 2017 Oct 30. Pharmacotherapy. 2017. PMID: 28891099 Review.
- Opioid and benzodiazepine withdrawal syndromes in the paediatric intensive care unit: a review of recent literature.Birchley G. Birchley G. Nurs Crit Care. 2009 Jan-Feb;14(1):26-37. doi: 10.1111/j.1478-5153.2008.00311.x. Nurs Crit Care. 2009. PMID: 19154308 Review.
- The Neonatal Withdrawal Assessment Tool (NWAT): pilot inter-rater reliability and content validity.Bektas G, Soderborg T, Slater C, Agarwal J, Racioppi M, Hogan T, Werler MM, Wachman EM. Bektas G, et al. J Perinatol. 2023 Mar 13. doi: 10.1038/s41372-023-01641-4. Online ahead of print. J Perinatol. 2023. PMID: 36914798
- Strategies for the management and prevention of withdrawal syndrome in critically ill pediatric patients: a systematic review.Klein K, Pereira JS, Curtinaz KALJ, Jantsch LB, Souza NS, Carvalho PRA. Klein K, et al. Rev Bras Ter Intensiva. 2022 Oct-Dec;34(4):507-518. doi: 10.5935/0103-507X.20220145-pt. Rev Bras Ter Intensiva. 2022. PMID: 36888832 Free PMC article.
- Evaluation of an Enteral Clonidine Taper following Prolonged Dexmedetomidine Exposure in Critically Ill Children.Crabtree MF, Sargel CL, Cloyd CP, Tobias JD, Abdel-Rasoul M, Thompson RZ. Crabtree MF, et al. J Pediatr Intensive Care. 2021 Mar 23;11(4):327-334. doi: 10.1055/s-0041-1726091. eCollection 2022 Dec. J Pediatr Intensive Care. 2021. PMID: 36388076 Free PMC article.
- Development and pilot testing of PROACTIVE: A pediatric onco-critical care capacity and quality assessment tool for resource-limited settings.Arias AV, Sakaan FM, Puerto-Torres M, Al Zebin Z, Bhattacharyya P, Cardenas A, Gunasekera S, Kambugu J, Kirgizov K, Libes J, Martinez A, Matinyan NV, Mendez A, Middlekauff J, Nielsen KR, Pappas A, Ren H, Sharara-Chami R, Torres SF, McArthur J, Agulnik A. Arias AV, et al. Cancer Med. 2023 Mar;12(5):6270-6282. doi: 10.1002/cam4.5395. Epub 2022 Nov 2. Cancer Med. 2023. PMID: 36324249 Free PMC article.
- Risk Factors Associated With Opioid/Benzodiazepine Iatrogenic Withdrawal Syndrome in COVID-19 Acute Respiratory Distress Syndrome.Maffei MV, Laehn S, Bianchini M, Kim A. Maffei MV, et al. J Pharm Pract. 2022 Aug 5:8971900221116178. doi: 10.1177/08971900221116178. Online ahead of print. J Pharm Pract. 2022. PMID: 35930693 Free PMC article.
- Multicenter Study
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Validation Study
- Analgesics, Opioid / adverse effects*
- Benzodiazepines / adverse effects*
- Child
- Child, Preschool
- Female
- Humans
- Infant
- Male
- Monitoring, Physiologic / methods*
- Prospective Studies
- Reproducibility of Results
- Substance Withdrawal Syndrome / physiopathology*
- Analgesics, Opioid
- Benzodiazepines
- Full Text Sources
- Medical
![Figure 2. Comparison of opioid exposure levels…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2775493/bin/nihms-78618-f0002.jpg)
Source: PubMed